兰州大学学报（医学版）2025，Vol.51Issue(9)：37-45,9.DOI:10.13885/j.issn.2097-681X.2025.09.006
间充质干细胞作为2型糖尿病补充疗法有效性及安全性的Meta分析
Meta-analysis of the efficacy and safety of mesenchymal stem cells as a supplementary therapy for type 2 diabetes mellitus
摘要
Abstract
Objective To investigate the efficacy and safety of mesenchymal stem cells(MSC)in the treatment of type 2 diabetes mellitus(T2DM)at multiple time points using Meta-analysis,and to explore whether MSC therapy can be used as a complementary treatment for T2DM.Methods Two researchers independently con-ducted literature searches in PubMed,Web of Science,Cochrane Library,CNKI,Wanfang Database,and The Chinese Biomedical Literature Database.Studies were screened and data extracted according to inclusion and exclusion criteria.Meta-analysis was performed using RevMan 5.4 software.Results A total of 11 clinical trials on MSC treatment for T2DM were included in this study.Compared to baseline,significant reductions in glycated hemoglobin(HbA1c,MD:-1.12,95%CI:[-1.67,-0.57];MD:-1.34,95%CI:[-2.10,-0.57];MD:-1.06,95%CI:[-1.68,-0.45])and exogenous insulin dosage(MD:-22.68,95%CI:[-29.89,-15.47];MD:-25.34,95%CI:[-38.41,-12.26];MD:-27.45,95%CI:[-36.65,-18.24])were observed at 3,6,and 12 months post-treatment(P<0.01).Fasting blood glucose(FBG,MD:-1.10,95%CI:[-2.10,-0.10])and fasting C-peptide(MD:0.48,95%CI:[0.06,0.90])showed significant improvement only at 6 months post-treatment(P<0.05).Compared to the control group,the exogenous insulin dosage was significantly reduced at 3,6,and 12 months post-treatment(MD:-15.58,95%CI:[-18.26,-12.89];MD:-16.77,95%CI:[-30.09,-3.46];MD:-26.90,95%CI:[-29.59,-24.20],P<0.01).HbA1c showed significant reductions at 6 and 12 months post-treatment(MD:-0.62,95%CI:[-1.15,-0.09];MD:-0.75,95%CI:[-1.40,-0.11],P<0.05),and FBG showed significant reduction at 6 months post-treatment(MD:-0.83,95%CI:[-1.57,-0.09],P<0.05).The source of MSC(autologous/allogeneic)might be one of the factors contributing to the heterogeneity in HbA1c and FBG.No serious adverse reactions related to MSC treatment were reported,with common adverse reactions being transient fever and hypoglycemic events.Conclusion MSC treatment demonstrated a signifi-cant control over blood glucose levels and exogenous insulin dosage in T2DM patients across multiple time points,with a favorable safety profile.MSC therapy can be considered as a complementary treatment option for T2DM.关键词
间充质干细胞/2型糖尿病/干细胞移植/Meta分析/再生医学Key words
mesenchymal stem cell/type 2 diabetes mellitus/stem cell transplantation/Meta analysis/regener-ative medicine分类
医药卫生引用本文复制引用
张皓承,苏媛,王晓辉,高保东,哈小琴..间充质干细胞作为2型糖尿病补充疗法有效性及安全性的Meta分析[J].兰州大学学报（医学版）,2025,51(9):37-45,9.基金项目
国家自然科学基金资助项目(81273568) （81273568）
甘肃省卫生健康行业科研计划基金资助项目(GSWSKY2022-03) （GSWSKY2022-03）
